Comparative Bioavailability of a Novel Fixed‐dose Combination Etoricoxib and Tramadol

• Published in: Clinical pharmacology in drug development Vol. 13; no. 11; pp. 1253 - 1259
• Main Authors: Garza‐Ocañas, Lourdes, Badillo‐Castaneda, Christian T., Eguía, Sandra L. Montoya, Zanatta‐Calderón, María T., Garza, Julia D. Torres, Gómez‐Meza, Marco Vinicio, Sander‐Padilla, José G., Lugo‐Sánchez, Laura A., Rios‐Brito, Kevin F., Romero‐Antonio, Yulia, González‐Canudas, Jorge
• Format: Journal Article
• Language: English
• Published: United States 01.11.2024
• Subjects: Administration, Oral; Adult; Analgesics, Opioid - administration & dosage; Analgesics, Opioid - adverse effects; Analgesics, Opioid - blood; Analgesics, Opioid - pharmacokinetics; Area Under Curve; bioavailability; Biological Availability; Cross-Over Studies; Cyclooxygenase 2 Inhibitors - administration & dosage; Cyclooxygenase 2 Inhibitors - adverse effects; Cyclooxygenase 2 Inhibitors - blood; Cyclooxygenase 2 Inhibitors - pharmacokinetics; Drug Combinations; etoricoxib; Etoricoxib - administration & dosage; Etoricoxib - adverse effects; Etoricoxib - pharmacokinetics; Female; Healthy Volunteers; Humans; Longitudinal Studies; Male; Mexico; non‐interaction; pharmacokinetics; Prospective Studies; Pyridines - administration & dosage; Pyridines - adverse effects; Pyridines - blood; Pyridines - pharmacokinetics; tramadol; Tramadol - administration & dosage; Tramadol - adverse effects; Tramadol - pharmacokinetics; Young Adult; Mexico; non‐interaction; pharmacokinetics; tramadol; bioavailability; etoricoxib
• ISSN: 2160-763X; 2160-7648
• DOI: 10.1002/cpdd.1456

Multimodal analgesia is defined as using several drugs or techniques simultaneously to target different pain pathways or receptors to avoid pain propagation. This study evaluated the pharmacokinetic profile and comparative bioavailability of etoricoxib 90 mg and tramadol 50 mg dosing alone (reference drugs) or in a novel fixed‐dose combination (test drug) under fasting conditions in Mexican healthy volunteers. This was a randomized, open‐label, 3‐way, crossover, single‐dose, prospective, and longitudinal study with a 14‐day washout period. Eligible subjects were healthy Mexican adult volunteers. The drugs were dosing orally, according to the randomization sequence, after 10 hours of fasting and 4 hours before breakfast with 250 mL of water at room temperature. Serial blood samples were collected before and after dosing, both drugs were quantified using high‐performance liquid chromatography coupled with tandem mass spectrometry. Forty‐two subjects were enrolled and 38 completed the study (28 men and 14 women, mean age 25.2 years, mean weight 66.6 kg). Test products were considered to have comparative bioavailability if confidence intervals of natural log‐transformed for (maximum plasma drug concentration (Cmax), (area under the plasma drug concentration‐time curve form 0 up to last sampling time (AUC0‐t), and (area under the plasma drug concentration‐time curve from 0 up to infinity (AUC0‐∞) data were within the range of 80%‐125%. Non‐serious adverse events were observed. The results demonstrate that the pharmacokinetic profile and bioavailability of the etoricoxib/tramadol fixed‐dose combination are comparable to those of the reference products.